Scynexis Inc SCYX

$3.52 +0.02 (0.57%)

Valuation

Market cap
34,824,000
Revenue TTM
$20,600,000
Net income TTM
$-8,610,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-41.80%
Debt to equity
0.00

Trading

Volume
37,354
Avg volume
260,992
Day's range
$3.45 – $3.67
Shares out
9,950,000
Stochastic %K
29%
Beta
1.15
Analysts
Strong Buy
Price target
$32.67

Price

Company profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fu...

Show more

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
201 884 5485
Website
https://www.scynexis.com
Address
1 Evertrust Plaza, 13th Floor, Jersey City, United States

Latest news

Stocktwits

Justfactsplease Nov 10, 5:10 PM
$SCYX same posters spreading FUD here every week for years. Click on profiles, look at the history-- easy to tell who the shills are.
0 replies
Merlintrader Nov 9, 8:30 PM
$SCYX SCYNEXIS files $200 million shelf registration on Form S-3 (Nov 5) • SCYNEXIS filed a Form S-3 shelf registration statement with the SEC on November 5, 2026, covering up to $200,000,000 of common stock, preferred stock, debt securities and warrants. • The filing replaces the company's Form S-3 (File No. 333-275520), which is due to expire on November 27, 2026, and carries forward $200,000,000 of unsold securities without an additional registration fee. Full hub (catalysts, filings & latest news): https://www.merlintrader.com/scynexis-scyx-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=scyx Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE: https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=scyx Not investment advice.
0 replies
yanlucas Nov 9, 1:07 PM
$SCYX I’ve closed my short position; I don’t trust the news that might come out of today’s presentation—better to sit on the sidelines.
0 replies
LemuelPitkin Nov 6, 2:29 AM
$SCYX It's time to be honest. Electing a. Democrat-majority in Congress and the Senate has cost the stock market over a trillion dollars. This political and market clown show is just going to get worse and worse until the 2028 election. The Democrat socialist-clowns of America are an expensive self-punishment.
1 replies
DataJim Nov 5, 11:46 PM
$SCYX The shelf is just a renewal of a shelf that is expiring and which has not been used. In fact, when they raised funds, they were able to do it above market rate, which is unusual and well done.
1 replies
pantarei Nov 5, 10:24 PM
$SCYX probably the worst managed company in the entire market. An absolute scam pos. Be aware!
0 replies
ViktorSinclair Nov 5, 5:55 PM
$SCYX Yet another *** ALL TIME LOW *** When will the BOD pull the plug on this management team? They are idiots when it comes to running a public company. They have the communication skills of a cement block. Enough with the re-phrased PR's that we already know what they say. Answer the hard awkward questions that investors have.
0 replies
Merlintrader Nov 5, 4:47 PM
$SCYX : SCYNEXIS Q3 2026 and $200M shelf (reported Nov 5): Q3 revenue nil; net loss $8.5M, $(0.71) per share; cash, equivalents and investments $63.2M at Sept 30 (vs $71.1M at June 30); Form S-3 shelf filed Nov 5 covering up to $200M of securities; SCY-770 Phase 2 start still guided to Q4 2026; SCY-247 Phase 2 expected in 2027 subject to FDA agreement. Questions worth checking: What is the next SCYX stock catalyst? How much cash does SCYNEXIS have, and how long is it funded? Are SCY-770 and SCY-247 FDA approved? Answers, primary sources and downloadable PDF report in our hub: https://www.merlintrader.com/scynexis-scyx-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=scyx_hubpdf_nov26 Not investment advice.
1 replies